NPI-002
Asset
Provides sustained antioxidant activity in the eye to reduce oxidative damage and delay cataract progression.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Oxidative stress and ROS signalling
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Cataract
Phase 1, Completed, NCT05026632, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.